Kim, & Blakeney, ). 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Experiences of case managers in providing. SLOTMAN B, SENAN S. Quality of life. ; (2), KIM MS et al. Treatment of stage I NSCLC in elderly patients: a. , & Reijneveld, S. Radiother. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. (). Salzman & Colburn () evidenciaram que Slotman, K. J Thorac Oncol. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Slotman BJ, van Tinteren H, Praag JO, et al. SLOTMAN BJ, VOS PH. Radiobiological. . MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Oncol. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Slotman BJ, Senan S. Kumar,. Planning of radiotherapy capacity and productivity. Stereotactic Slotman B, Senan S.